Coya Therapeutics received FDA Fast Track Designation for COYA 302, its investigational dual-mechanism biologic therapy for amyotrophic lateral sclerosis (ALS). The company is currently evaluating the therapy in the Phase 2 ALSTARS trial.
Written By: Karthik Teja Macharla, PharmD
Reviewed By: Pharmacally Editorial Team
Coya Therapeutics announced that the U.S. Food and Drug Administration has granted Fast Track Designation to COYA 302, the company’s investigational biologic combination therapy for the treatment of amyotrophic lateral sclerosis (ALS).
The FDA’s Fast Track program is intended to support the development and review of therapies for serious or life-threatening conditions with unmet medical needs. The designation may provide several regulatory advantages, including more frequent interactions with the FDA, eligibility for rolling review, and potential access to expedited pathways such as Accelerated Approval and Priority Review.
COYA 302 is a proprietary biologic combination therapy designed with a dual immunomodulatory mechanism aimed at improving regulatory T cell (Treg) function while reducing inflammation driven by activated monocytes and macrophages.
The therapy combines proprietary low-dose interleukin-2 (LD IL-2) with CTLA-4 Ig and is being developed as a subcutaneous treatment for patients with ALS. According to the company, the combined mechanisms may produce additive or synergistic anti-inflammatory effects.
In a statement, Chief Executive Officer Arun Swaminathan, Ph.D., said the Fast Track designation highlights the serious nature of ALS and the continued need for additional treatment options. He added that the company plans to continue advancing COYA 302 through the regulatory process with the goal of potentially bringing a safe and effective therapy to patients with ALS, pending regulatory approval.
Coya is currently evaluating COYA 302 in the ongoing ALSTARS Trial (NCT07161999), a Phase 2 randomized, multi-center, double-blind, placebo-controlled study assessing the therapy’s efficacy and safety in patients with ALS.
COYA 302 remains an investigational therapy and has not been approved by the FDA or any other regulatory authority.
Reference
Study Details | NCT07161999 | Study of COYA 302 for the Treatment of ALS | ClinicalTrials.gov
About the Writer
Karthik Teja Macharla, PharmD (LinkedIn) is a Pharm.D. graduate with a strong interest in clinical research, pharmacovigilance, and medical writing. In his words, he is passionate about converting complex medical information into clear, evidence-based scientific communication, committed to contributing to patient safety and advancing healthcare through accurate and impactful medical content.